DnaJB8 Inhibitors

DnaJB8 inhibitors primarily function by inhibiting the heat shock proteins (HSPs) that DnaJB8 associates with. DnaJB8 is a co-chaperone that aids in protein folding and maturation, functioning in complexes with HSP70 and HSP90. Therefore, inhibitors of these HSPs can lead to a decrease in the functional activity of DnaJB8. Geldanamycin, 17-AAG, and Radicicol are all HSP90 inhibitors that disrupt the HSP70-HSP90 complexes and thus reduce DnaJB8's functional activity. By inhibiting HSP90, these compounds disrupt the chaperone complexes, affecting the protein folding and maturation process that DnaJB8 is involved in. In a similar vein, VER-155008, MKT-077, Apoptozole, and JG-98 are HSP70 inhibitors that, by inhibiting HSP70, decrease the functional activity of DnaJB8. These inhibitors disrupt the chaperone complexes, leading to a decrease in protein folding and maturation where DnaJB8 is a co-contributor. Furthermore, some inhibitors function by influencing other pathways that indirectly affect DnaJB8's functionality. Cycloheximide inhibits protein synthesis and thus indirectly impedes the protein folding process that DnaJB8 aids. Tunicamycin inhibits glycosylation, a post-translational modification, indirectly affecting DnaJB8's role in protein folding and maturation. MG132 and Bortezomib are proteasome inhibitors. As DnaJB8 can participate in protein degradation pathways, altering these pathways can indirectly affect the functionality of DnaJB8.